Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Differentiated Thyroid Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 7trametinib 5pembrolizumab 5selpercatinib 4dabrafenib 4Specimen Handling 4Nivolumab 4cabozantinib 3Iodine-131 3spartalizumab 2omipalisib 2lenvatinib 2durvalumab 2binimetinib 2Vemurafenib 2Sorafenib 2Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1sapanisertib 1relatlimab 1regorafenib 1pertuzumab 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Neoplasms × Iodine-124 × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡